Daiichi Sankyo-AstraZeneca Gets BLA Approved for Lung Cancer Therapy in the U.S.
DATO-DXD jointly developed by Daiichi Sankyo/AstraZeneca (AZN.US)
On February 19, Daiichi Sankyo/AstraZeneca (AZN.US) jointly announced that its dato-DXD biological product license application (BLA) was accepted by the FDA for use in adult patients with locally advanced or metastatic non-squamous NSCLC who have previously received systemic treatment. The PDUFA date is December 20, 2024.
Pharma Giants Turn to China in Search of Targeted Cancer Drugs
Daiichi Sankyo Reports 9M Results
Merck Posts Q4 Beat as Keytruda Outperforms
DAIICHI SANKYO COMPANY LIMITED To Go Ex-Dividend On March 28th, 2024 With 0.264 USD Dividend Per Share
February 1st - $DAIICHI SANKYO COMPANY LIMITED(DSKYF.US)$ is trading ex-dividend on March 28th, 2024. Shareholders of record on March 31st, 2024 will receive 0.264 USD dividend per share on June 2
AstraZeneca Says Enhertu Application for HER2-Positive Solid Tumors Slated for FDA Priority Review
AstraZeneca (AZN) and Daiichi Sankyo said Monday their supplemental biologics license application for Enhertu was granted priority review by the US Food and Drug Administration.
AstraZeneca/ Daiichi Win FDA Priority Review for Enhertu Label Expansion
Accepting the sBLA for priority review, the regulator has issued May 30, 2024, as the Prescription Drug User Fee Act (PDUFA) date for its decision.
What's Going On With Pfizer Stock Today?
Pfizer Inc (NYSE:PFE) is set to announce its fourth quarter 2023 earnings next week on 30th January. The analysts expect the US pharma giant to report an EPS loss of $(0.22) and revenues of $14.25 bil
Gilead in Selloff After Late-stage Setback for Trodelvy
Pfizer Faces Setback in Enhertu Patent Dispute With Daiichi
J.P. Morgan Event in Spotlight as Biotech M&A, Obesity Frenzy, AI Pick up
Daiichi Sankyo/AstraZeneca (AZN.US) “detrastuzumab” to be included as a breakthrough treatment
Destrastuzumab is an antibody conjugate drug (ADC) targeting HER2 developed jointly by AstraZeneca (AZN.US) and Daiichi Sankyo.
Patritumab Deruxtecan Granted Priority Review in the U.S. for Certain Patients With Previously Treated Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
Daiichi Sankyo (TSE: 4568) and Merck (NYSE: MRK) announced today that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the Biologics License Application (BLA) for patritumab deruxtecan (HER3-DXd) for the treatment of adult patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) previously treated with two or more systemic therapies.
AbbVie-Immunogen Buyout Deal Lifts ADC-focused Biotechs
Daiichi Sankyo GAAP EPS of ¥50.56, Revenue of ¥726.34B
Deciphera Reaches Main Goal in Phase 3 Trial for Rare Joint Tumor
Merck Lifts 2023 Outlook Amid Strong Sales for COVID-19 Pill
AstraZeneca, Daiichi Sankyo's Breast Cancer Combo Shrinks Tumors in Early-stage Study
AstraZeneca (AZN.L, AZN.ST) and Daiichi Sankyo (D4S.F) said Sunday that datopotamab deruxtecan combined with Imfinzi reduced the tumor size of certain breast cancer patients, citing new data from an early-stage trial.
Datopotamab Deruxtecan Plus Durvalumab Demonstrated Robust and Durable Tumor Responses in First-Line Treatment of Patients With Metastatic Triple Negative Breast Cancer in BEGONIA Phase 1b/2 Trial
Daiichi Sankyo and AstraZeneca's datopotamab deruxtecan plus durvalumab showed a confirmed objective response rate of 79%.